Modes of action of ipilimumab and biomarkers of resistance to therapy in patients

Dalil Hannani; Marie Vétizou; David Enot; Sylvie Rusakiewicz; Sophie Viaud; D. Klazmann; Nathalie Chaput; Alexander M.M. Eggermont; Guido Guido Kroemer; Caroline Robert; Laurence Zitvogel

doi:10.1016/j.annder.2013.09.653

Related publications

Article2008

Modes of resistance to anti-angiogenic therapy

Gabriele Bergers, Douglas Hanahan

Article2019

Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis

Sarah C. Sasson, John Zaunders, Kazi Nahar, C. Mee Ling Munier, Scott Read, Golo Ahlensteil, Umaimainthan Palendira, Richard A Scolyer, Matteo S. Carlino, Georgina V. Long, Alexander M. Menzies, Anthony D. Kelleher

Chapter in a book1984

Modes of action of interferon and analogues of 2-5A, a mediator of interferon action

De Clercq Erik, J. Content, Paola Defilippi, Jan Balzarini, Johan Warrinnier, Hiroaki Sawai, Junta Imai, Krystyna Lesiak, Jean Claude Jamoulle, Paul F. Torrence

Article2021

Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders

Lauren Brown, Alison M. Weppler, Prachi Bhave, Clara Allayous, James R. Patrinely, Patrick A. Ott, Shahneen Sandhu, Andrew Haydon, Célèste Lebbé, Douglas B. Johnson, Georgina V. Long, Alexander Menzies, Matteo S. Carlino

Article2021

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, Alison M. Weppler, Allison Betof Warner, James R. Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L. Gérard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Célèste Lebbé, Paul Lorigan,